145 related articles for article (PubMed ID: 35577625)
1. Factor-guided diagnosis of coagulopathy associated with coumarin-contaminated synthetic cannabinoids.
Torian SC; Hayes L; Negrete A
Am J Emerg Med; 2022 Aug; 58():350.e5-350.e6. PubMed ID: 35577625
[TBL] [Abstract][Full Text] [Related]
2. Synthetic cannabinoid-associated coagulopathy secondary to long-acting anticoagulant rodenticides: Observational case series and management recommendations.
Bahouth MN; Kraus P; Dane K; Plazas Montana M; Tsao W; Tabaac B; Jasem J; Schmidlin H; Einstein E; Streiff MB; Shanbhag S
Medicine (Baltimore); 2019 Sep; 98(36):e17015. PubMed ID: 31490385
[TBL] [Abstract][Full Text] [Related]
3. An Outbreak of Synthetic Cannabinoid-Associated Coagulopathy in Illinois.
Kelkar AH; Smith NA; Martial A; Moole H; Tarantino MD; Roberts JC
N Engl J Med; 2018 Sep; 379(13):1216-1223. PubMed ID: 30280655
[TBL] [Abstract][Full Text] [Related]
4. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms.
Dentali F; Ageno W; Crowther M
J Thromb Haemost; 2006 Sep; 4(9):1853-63. PubMed ID: 16961594
[TBL] [Abstract][Full Text] [Related]
5. Management of coumarin-associated coagulopathy in the non-bleeding patient: a systematic review.
Dentali F; Ageno W
Haematologica; 2004 Jul; 89(7):857-62. PubMed ID: 15257939
[TBL] [Abstract][Full Text] [Related]
6. Radiological findings in poisoning by synthetic cannabinoids adulterated with brodifacoum.
Bar N; Lopez-Alonso R; Merhav G; Naaman E; Leiderman M; Ilivitzki A; Lurie Y; Kurnik D; Abadi S
Eur Radiol; 2024 Jul; 34(7):4540-4549. PubMed ID: 38127072
[TBL] [Abstract][Full Text] [Related]
7. Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs.
Chase PB; Hawkins J; Mosier J; Jimenez E; Boesen K; Logan BK; Walter FG
Clin Toxicol (Phila); 2016; 54(1):14-9. PubMed ID: 26653952
[TBL] [Abstract][Full Text] [Related]
8. Bad weed: synthetic cannabinoid-associated coagulopathy.
Arepally GM; Ortel TL
Blood; 2019 Feb; 133(9):902-905. PubMed ID: 30655273
[TBL] [Abstract][Full Text] [Related]
9. An outbreak of severe coagulopathy in northern Israel among users of illicit synthetic cannabinoids adulterated with brodifacoum.
Lurie Y; Nadir Y; Hoffman R; Miller A; Efrati E; Ring G; Sonenfeld D; Bar N; Zaidani H; Strizevsky A; Asali M; Lavon O; Kurnik D
Clin Toxicol (Phila); 2023 Jun; 61(6):429-435. PubMed ID: 37293741
[TBL] [Abstract][Full Text] [Related]
10. Synthetic cannabinoid use: recognition and management.
Castellanos D; Thornton G
J Psychiatr Pract; 2012 Mar; 18(2):86-93. PubMed ID: 22418399
[TBL] [Abstract][Full Text] [Related]
11. Brodifacoum-contaminated synthetic marijuana: clinical and radiologic manifestations of a public health outbreak causing life-threatening coagulopathy.
Panigrahi B; Jones BC; Rowe SP
Emerg Radiol; 2018 Dec; 25(6):715-718. PubMed ID: 30022308
[TBL] [Abstract][Full Text] [Related]
12. Hemorrhagic Soft Tissue Upper Airway Obstruction From Brodifacoum-Contaminated Synthetic Cannabinoid.
Ross CH; Singh P; Simon EL
J Emerg Med; 2019 Jul; 57(1):47-50. PubMed ID: 31078349
[TBL] [Abstract][Full Text] [Related]
13. Brodifacoum contamination of synthetic cannabinoid causing unexplained coagulopathy in multiple trauma: A case report.
Thomas AV; Johnson ML; Tincher AM; Zackariya S; Khan H; Rizvi U; Thomas SG; Noveroske TW; Fulkerson DH; Moore EE; Walsh MM
Trauma Case Rep; 2024 Jun; 51():101007. PubMed ID: 38590923
[TBL] [Abstract][Full Text] [Related]
14. Persistent Coagulopathy After Synthetic Cannabinoid Use.
Haider M; Acevedo-Cajigas C; Ortiz D; Zorrilla CA; Perez J
Cureus; 2023 Mar; 15(3):e36156. PubMed ID: 37065401
[TBL] [Abstract][Full Text] [Related]
15. Lethal coagulopathy resulting from the consumption of contaminated synthetic cannabinoids: the story of a public health crisis.
Fasih A
J Public Health (Oxf); 2021 Apr; 43(1):e1-e6. PubMed ID: 31242305
[TBL] [Abstract][Full Text] [Related]
16. Coagulopathic hemorrhage with use of synthetic cannabinoids.
Boyack I; Opsha O
Am J Emerg Med; 2019 Feb; 37(2):374.e3-374.e4. PubMed ID: 30409461
[TBL] [Abstract][Full Text] [Related]
17. The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review.
Alves VL; Gonçalves JL; Aguiar J; Teixeira HM; Câmara JS
Crit Rev Toxicol; 2020 May; 50(5):359-382. PubMed ID: 32530350
[TBL] [Abstract][Full Text] [Related]
18. Synthetic cannabinoid use among college students.
Mathews EM; Jeffries E; Hsieh C; Jones G; Buckner JD
Addict Behav; 2019 Jun; 93():219-224. PubMed ID: 30772774
[TBL] [Abstract][Full Text] [Related]
19. Coagulopathy After Synthetic Cannabinoid Use: A Case Report.
Rasin A; Devgun JM; Nosal DG; Meehan TJ; van Breemen RB; Thompson TM
Ann Intern Med; 2019 Oct; 171(8):595-596. PubMed ID: 31450243
[No Abstract] [Full Text] [Related]
20. Cannabis and synthetic cannabinoid exposure reported to the Israel poison information center: Examining differences in exposures to medical and recreational compounds.
Sznitman SR; Pinsky-Talbi L; Salameh M; Moed T; Bentur Y
Int J Drug Policy; 2020 Mar; 77():102711. PubMed ID: 32126489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
